PDF
3.87
MB
ISTH 2023 Montreal_HORIBA Medical Presentation Theater Program
This year again, HORIBA Medical will participate in the ISTH 2023 which will take place from June 24 to 28 in Montreal. The International Society on Thrombosis and Haemostasis (ISTH) Annual Congress is the premier event in the field of thrombosis and hemostasis featuring the latest scientific breakthroughs and clinical updates. This conference brings together researchers, physicians and biologists specialized in hemostasis, usually between 5,000 and 10,000 attendees. During this Congress, HORIBA Medical will open an exhibition booth to showcase the latest innovations in hemostasis, and host a presentation theater where three key opinion leaders will talk about current scientific medical topics.
The HORIBA Medical team is looking forward to welcoming you there!
Dr. Steve KITCHEN
Lead Clinical Scientist, Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre - UK
Dr. Emmanuelle JEANPIERRE
Hematology Transfusion Institute of Lille University Hospital - France
Mr. Kevin HORNER
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre - UK
Prof. Corinne FRERE
Biological Hematology Department of Pitié-Salpêtrière University Hospital – France
1. Dr. Emmanuelle JEANPIERRE
Hematology Transfusion Institute of Lille University Hospital - France
Sensitivity of three new Prothrombin Time reagent to extrinsic pathway factor deficiencies.
Prothrombin time is widely used for monitoring vitamin K antagonist-based anticoagulant therapy but also as a screening test for extrinsic factor deficiency (congenital or acquired). The sensitivity of three new reagents (Yumizen G PT 5, Yumizen G PT Reco, and Yumizen G PT Liq ) was compared with that of two other reagents available in the laboratory (STA-Neo R and STA-NeoPTimal). For all five reagents, the analyses were performed on Yumizen G1550 and STAGO STA-R Max 2 to compare the performance of each reagent/instrument combination.
2. Mr. Kevin HORNER
Department of Coagulation, Sheffield Haemophilia and Thrombosis Centre - UK
Evaluation of the new Preanalytical HIL (Haemolysis, Icterus & Lipemia) on HORIBA Medical analysers.
Haemolysis, Icterus and Lipemia have been reported to cause interference in haemostasis assays, which may unpredictably vary between different reagent analyser combinations. The ability to determine each indice is a mainstay for determining sample quality. We report on findings of our evaluation looking at both spurious and native samples.
3. Prof. Corinne FRERE
Biological Hematology Department of Pitié-Salpêtrière University Hospital – France
Performance evaluation of the ACTICHROME Heparin Anti-Xa™ assay for the quantitative determination of UFH and LMWH plasma concentrations.
The ACTICHROME Heparin Anti-Xa™ assay (HORIBA Medical) is a newly launched, specific, easy to use and fully automated chromogenic assay for the quantitative determination of plasma concentrations of unfractionated heparin (UFH) and low-molecular-weight heparin (LMWH). We report on findings of our evaluation of this new reagent.
Do you have any questions or requests? Use this form to contact our specialists.
